Lipoprotein(a) in Men Over 40: The Inherited Risk Marker You Only Need To Test Once

A man can eat well, train five days a week, hold an LDL of 90 and a waist under 90 centimetres, and still carry a particle that roughly triples his cardiovascular risk without ever appearing on his blood report. Lipoprotein(a) is not measured by a standard lipid panel, is not meaningfully changed by diet or exercise, and is set almost entirely by a gene he inherited before birth. Around one in five people carries an elevated level. This article covers what the particle is, what the nmol/L thresholds mean, why the genetic evidence is unusually strong, what actually moves the number and what does not, how androgens including testosterone therapy interact with it, and what the drugs currently in phase 3 outcomes trials are attempting.

Lipoprotein(a), written Lp(a) and spoken as L-P-little-a, is an LDL particle carrying an extra protein called apolipoprotein(a) bolted onto its apoB-100 by a disulfide bond. That single structural difference changes what the particle does in an artery wall and how the body handles it. A standard lipid panel measuring total cholesterol, LDL, HDL and triglycerides does not detect it separately, so a man can review a decade of normal cholesterol reports without ever learning his Lp(a) is in the top five percent of the population.

Roughly 20 to 25 percent of people worldwide carry an Lp(a) above the commonly used high risk threshold of 125 nmol/L, which is about 1.4 billion people. The European Atherosclerosis Society consensus statement published in 2022 recommends measuring Lp(a) at least once in every adult's lifetime, and the 2018 ACC and AHA cholesterol guideline lists an Lp(a) above 50 mg/dL as a risk enhancing factor. Despite both recommendations, the test remains missing from most routine panels ordered for men in their forties and fifties.

Lipoprotein(a) is an LDL particle with apolipoprotein(a) attached, and that added protein is what makes it behave differently from ordinary LDL. Apolipoprotein(a) is structurally similar to plasminogen, the precursor of the enzyme that dissolves clots, which is the basis for the long standing hypothesis that Lp(a) interferes with fibrinolysis in addition to depositing cholesterol. The particle also carries a disproportionate share of the body's oxidized phospholipids, which are directly inflammatory in the artery wall.

Concentration of Lp(a) is controlled almost entirely by the LPA gene on chromosome 6, specifically by a region of repeated sequence called the kringle IV type 2 domain. The number of those repeats a man inherits determines how large his apolipoprotein(a) isoform is, and isoform size is inversely related to how much of the particle ends up in his blood. Fewer repeats produce a smaller isoform, faster secretion from the liver and a higher circulating concentration. This is why Lp(a) is stable from around age five, why it does not drift with diet, and why a father with a high level frequently has sons with high levels.

Above 125 nmol/L is the threshold most commonly used to define high risk, with under 75 nmol/L considered low and the band between the two treated as intermediate. Expressed in the older mass units those cut points are roughly 50 mg/dL and 30 mg/dL. A value above 430 nmol/L, which is around the 95th percentile in European ancestry populations, is often described as very high and is the range where clinicians in some countries consider lipoprotein apheresis for men who already have progressive coronary disease.

Ask the laboratory for a result in nmol/L rather than mg/dL, because the two units cannot be converted with a fixed factor. Mass units measure the weight of a particle whose weight varies with isoform size, so a mg/dL result systematically misestimates the particle count in men at both ends of the isoform range. Molar units in nmol/L count particles directly and are what the European Atherosclerosis Society recommends. Conversion factors circulating online, usually somewhere between 2.0 and 2.5, are approximations that fail worst in exactly the men whose results matter most.

The causal evidence for Lp(a) comes from Mendelian randomization, which is a stronger design than the observational studies underpinning most risk markers. Because the LPA variants that raise Lp(a) are assigned randomly at conception and are not correlated with diet, income, smoking or exercise, comparing people who inherited high producing variants against those who did not approximates a randomized trial run by nature. Kamstrup and colleagues published the landmark analysis in JAMA in 2009, showing that genetically elevated Lp(a) predicted myocardial infarction in the same direction and roughly the same magnitude as measured Lp(a).

That genetic result is the reason Lp(a) is treated differently from markers such as homocysteine, where the observational association was strong but the Mendelian randomization data did not support causation and the intervention trials failed. For Lp(a) the epidemiology, the genetics and the biology all point the same way. The Emerging Risk Factors Collaboration analysis in the Lancet in 2009, pooling more than 125,000 participants across 36 prospective studies, found a continuous association between Lp(a) and coronary disease that persisted after adjustment for conventional lipids.

Lp(a) is the only lipoprotein with a well established genetic link to calcific aortic valve disease, and the mechanism is thought to run through the oxidized phospholipids the particle carries. Valve leaflet tissue retains Lp(a), the oxidized lipid cargo drives local inflammation, and the valve interstitial cells respond by taking on a bone forming phenotype that lays down calcium. The Thanassoulis analysis in 2013 was the first to tie an LPA variant to both valve calcification on imaging and to clinically diagnosed stenosis.

For a man over 40 the practical relevance of the valve finding is that it explains why a high Lp(a) is worth knowing about even when the coronary picture looks clean. Ordinary LDL does not carry the same valve signal, so a man with high Lp(a) and otherwise unremarkable lipids has a risk profile that his lipid panel genuinely does not describe. That is a reason for a physician to know the number, not a reason for the man to self manage anything.

These proportions approximate the distribution reported in European ancestry cohorts and should not be read as exact figures. Lp(a) distribution differs substantially by ancestry, with populations of West African descent carrying median concentrations roughly two to three times higher than European ancestry populations and South Asian populations sitting between the two. Any percentile a laboratory prints on a report is derived from whichever reference population that laboratory used, which is one more reason to look at the absolute nmol/L value rather than the percentile.

No lifestyle intervention has been shown to lower Lp(a) meaningfully, and this is the single most important thing for a man to understand about the marker. Weight loss does not move it. Endurance training does not move it. Saturated fat restriction, which lowers LDL reliably, has if anything been reported to raise Lp(a) slightly in controlled feeding studies. There is no supplement with credible evidence behind it, and the products marketed for the purpose are trading on the fact that most men have never heard of the particle.

Statins do not lower Lp(a) either, and a 2020 meta-analysis by Tsimikas and colleagues in the Lancet found that statin therapy raises it modestly, in the region of 10 to 20 percent. That finding is not a reason to avoid a statin, since the LDL and apoB reduction a statin delivers dwarfs the small Lp(a) increase in terms of net risk, and every one of those decisions belongs to a prescribing physician. It is a reason to stop expecting a lipid drug to fix a marker it was never designed to touch.

Exogenous androgens lower Lp(a), and this is one of the more consistent lipid findings in the testosterone literature. Trials of testosterone therapy in hypogonadal men have reported Lp(a) reductions in the region of 20 to 30 percent, and older studies of synthetic androgens such as danazol and stanozolol reported larger falls still. The mechanism is not fully worked out and appears to involve reduced hepatic apolipoprotein(a) production rather than faster clearance of the assembled particle.

None of that makes testosterone therapy an Lp(a) treatment, and no trial has tested whether the androgen driven reduction changes cardiovascular outcomes. Testosterone therapy also affects other lipid parameters in ways that are not uniformly favourable, including reductions in HDL cholesterol, and its cardiovascular safety profile is a separate question addressed by trials such as TRAVERSE. A man already on prescribed testosterone therapy is worth measuring while on treatment, since his result reflects his current state rather than his untreated genetic baseline. Any decision about starting, stopping or dosing testosterone belongs with a licensed clinician.

Because Lp(a) itself cannot currently be lowered outside a clinical trial or a specialist clinic, a high result changes how aggressively everything else gets managed rather than adding a new target. The reasoning is additive risk. A man carrying an inherited particle burden he cannot alter has less room for the risk factors he can alter, which shifts the threshold at which a physician acts on blood pressure, apoB, glucose and smoking. Discovering a high Lp(a) at 44 is useful for exactly that reason, and it is useless if it never reaches a clinician.

Four targeted agents are in advanced development, and all of them work by shutting down hepatic production of apolipoprotein(a) rather than clearing the assembled particle. Pelacarsen is an antisense oligonucleotide that reduced Lp(a) by up to around 80 percent in the phase 2 trial published by Tsimikas and colleagues in 2020, and it is the furthest along in phase 3 outcomes testing. Olpasiran is a small interfering RNA that cut Lp(a) by more than 95 percent at higher doses in OCEAN(a)-DOSE. Lepodisiran is a longer acting siRNA reported to produce sustained reductions from infrequent dosing. Muvalaplin is an oral small molecule that blocks assembly of the particle rather than its synthesis.

This chart is an illustration of the general shape reported across phase 2 pharmacodynamic data rather than a reproduction of results from any single trial, and the specific depths and durations differ substantially by agent, dose and schedule. The pattern worth taking from it is that these therapies produce a deep reduction followed by a slow return toward baseline, which is what allows dosing intervals measured in months. What none of them has yet demonstrated is that lowering the particle lowers events, and that is precisely what the phase 3 outcomes trials were designed to answer.

The niacin story is the reason that distinction matters. Niacin lowers Lp(a) by roughly 20 percent, and both AIM-HIGH and HPS2-THRIVE found no cardiovascular benefit from adding it to statin therapy, with HPS2-THRIVE reporting an excess of serious adverse events. Moving a marker is not the same as reducing risk. Until an outcomes trial reads out, the honest position on Lp(a) lowering drugs is that the biology is compelling and the proof is not yet in.

Continue Reading

Related Articles

Hormones

Cholesterol, ApoB, and TRT: What Testosterone Therapy Actually Does to Your Lipid Panel

12 min read

Read Article →

Lab Markers

hs-CRP in Men Over 40: The Inflammation Marker Most Blood Panels Leave Off

11 min read

Read Article →

Nutrition

The Omega-3 Index in Men Over 40: The Blood Marker Almost Nobody Orders

13 min read

Read Article →